腎移植後内科・小児科系合併症の診療ガイドライン2011

出版社： 日本医学館
著者：
発行日： 2011-08-01
分野： 臨床医学：外科  >  移植/人工臓器
ISBN： 9784890447312
電子書籍版： 2011-08-01 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,375 円(税込)

購入する

目次

  • 表紙
  • 執筆者
  • はじめに
  • はじめに
  • Contents
  • 凡例
  • GUIDE 1[要約]～7[要約]
  • [1] 腎移植後高血圧
  • [2] 腎移植後発症糖尿病
  • [3] 腎移植後脂質異常症
  • [4] 腎移植後高尿酸血症
  • [5] 腎移植後肥満・体重増加
  • [6] 腎移植後メタボリックシンドローム
  • [7] 腎移植後成長 (最終身長)
  • GUIDE 1～7
  • [1] 腎移植後高血圧
  • [2] 腎移植後発症糖尿病
  • [3] 腎移植後脂質異常症
  • [4] 腎移植後高尿酸血症
  • [5] 腎移植後肥満・体重増加
  • [6] 腎移植後メタボリックシンドローム
  • [7] 腎移植後成長 (最終身長)
  • 参考文献
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

参考文献

P.59 掲載の参考文献
1) Midtvedt K, Neumayer HH:Management strategies for posttransplant hypertension. Transplantation 70 (11 Suppl):64-69, 2000.
 
2) Koomans HA, Ligtenberg G:Mechanisms and consequences of arterial hypertension after renaltransplantation. Transplantation 72 (6 Suppl):9-12, 2001.
 
3) 両角國男, 武田朝美, 打田和治:免疫抑制薬による腎障害. 腎と透析 47:357-364, 1999.
 
4) Curtis JJ:Cyclosporine and posttransplant hypertension. Am Soc Nephrol 2 (12 Suppl):243-245, 1992.
 
5) McGregor DO, Olsson C, Lynn KL:Autonomic dysfunction and ambulatory blood pressure inrenal transplant recipients. Transplantation 71:1277-1281, 2001.
 
6) Bruno S, Remuzzi G, Ruggenenti P:Transplant renal artery stenosis. J Am Soc Nephrol 15:134-141, 2004.
PubMed
7) Guidi E, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G:Hypertension may betransplanted with the kidney in humans:a long-term historical prospective follow-up recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol 7:1131-1138, 1996.
PubMed
8) Midtvedt K, Neumayer HH:Management strategies for posttransplant hypertension. Transplantation 70 (11 Suppl):64-69, 2000.
 
9) Tedla F, Hayashi R, McFarlane SI, Salifu MO:Hypertension after renal transplant. J Clin Hypertens (Greenwich) 9:538-545, 2007.
PubMed
10) 日本臨床移植学会, 日本移植学会:腎移植臨床登録集計報告(2007)-3. 2006年経過追跡調査報告. 移植 42:545-557, 2007.
 
11) Tutone VK, Mark PB, Stewart GA, Tan CC, Rodger RS, Geddes CC, Jardine A:Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant 19:181-192, 2005.
 
12) Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, O'Shaughnessy EA, Dahl DC, Silkensen JR, Sahadevan M, Snyder JJ:Hypertension after kidney transplantation. Am J Kidney Dis 43:1071-1081, 2004.
PubMed
13) Opelz G, Wujciak T, Ritz E:Association of chronic kidney graft failure with recipient bloodpressure. Collaborative Transplant Study. Kidney Int 53:217-222, 1998.
 
14) Mange KC, Cizman B, Joffe M, Feldman HI:Arterial hypertension and renal allograft survival. JAMA 283:633-638, 2000.
PubMed
15) Lipkin GW, Tucker B, Giles M, Raine AE:Ambulatory blood pressure and left ventricular mass incyclosporin-and non-cyclosporin-treated renal transplant recipients. J Hypertens 11:439-442, 1993.
PubMed
16) EBPG Expert Group on Renal Transplantation.:European best practice guidelines for renal transplantation. Section IV:Long-term management of the transplant recipient. IV. 5. 2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 17 (Suppl 4):25-26, 2002.
 
17) K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease:Guideline 1:goals of antihypertensive therapy in CKD. Am J Kid Dis 43 (Suppl 1):1-290, 2004.
 
18) CKD診療ガイド降圧療法. 日本腎臓学会・編, 東京医学社, 2007.
 
19) 高血圧治療ガイドライン2009. 日本高血圧学会・編. ライフサイエンス出版, 2009.
 
20) Keven K, YalCin S, Canbakan B, Kutlay S, SengUl S, Erturk S, Erbay B:The impact of dailysodium intake on posttransplant hypertension in kidney allograft recipients. Transplant Proc 38:1323-1326, 2006.
PubMed
21) Andres A, Morales E, Morales JM:Valsartan in Renal Transplantation Group:Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation:a randomized multicenter study. Transplant Proc 38:2419-2423, 2004.
 
22) Formica RN Jr, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ:A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 21:1389-1394, 2004.
 
23) Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, Hohage H:Long-termfollow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure andkidney function in renal transplant recipients. Transpl Int 16:313-320, 2003.
 
24) Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y:Lacidipine Study Group:Calcium channel blockade and preservation of renal graft function in cyclosporinetreated recipients:a prospective randomized placebo-controlled 2-year study. Transplantation 78:1204-1211, 2004.
 
25) Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyere F, Lebranchu Y:Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients:a prospective randomized trial. Clin Transplant 21:277-284, 2007.
PubMed
26) Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Kretz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC:New-onset diabetes after transplantation:2003 International consensus guidelines. Transplantation 5:3-24, 2003.
 
27) Davidson JA, Wilkinson A:New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines:an endocrinologist's view. Dibetes Care 27:805-812, 2004.
 
28) Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantie H, Villamil F, Vincenti F, Wissing M:Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19:291-298, 2005.
 
29) Bloom RD, Crutchlow MF:New-onset diabetes mellitus in the kidney recipient:diagnosis and management strategies. Clin J Am Soc Nephrol 3:38-48, 2008.
 
30) Crutchlow MF, Bloom RD:Transplant-associated hyperglycemia:a new look at an old problem. Clin J Am Soc Nephrol 2:343-355, 2007.
 
31) Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM:KDIGO clinical practice guideline for the care of kidney transplant recipients:a summary. Kidney Int 77:299-311, 2010.
PubMed
32) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (Suppl 3):66-70, 2009.
 
33) Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM:Post-transplant diabetes mellitus:increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 59:732-737, 2001.
PubMed
34) Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ:Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3:178-185, 2003.
PubMed
35) Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD:New onsethyperglycemia and diabetes are associated with increased cardiovascular risk after kidneytransplantation. Kidney Int 67:2415-2421, 2005.
 
36) Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB:beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71:1417-1423, 2001.
PubMed
37) Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM:Patient survival after renal transplantation:IV. Impact of post-transplant diabetes. Kindey Int 62:1440-1446, 2002.
 
38) Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM:Influence ofdiabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15:89-94, 2001.
 
39) Lentine KL, Brennan DC, Schnitzler MA:Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16:496-506, 2005.
PubMed
40) Ducloux D, Kazory A, Chalopin JM:Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients:a prospective study. Transplantation 79:438-443, 2005.
PubMed
41) Kasiske BL, Chakkera HA, Roel J:Explained and unexplained ischemic heart disease risk afterrenal transplantation. J Am Soc Nephrol 11:1735-1743, 2000.
 
42) 科学的根拠に基づく糖尿病診療ガイドライン 改定第2版. 日本糖尿病学会, 南江堂, 2004.
 
43) Armstrong KA, Prins JB, Beller EM, Campbell SB, Hawley CM, Johnson DW, Isbel NM:Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 1:100-108, 2006.
PubMed
44) Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC:Posttransplantation diabetes:a systematic review of the literature. Diabetes Care 25:583, 2002.
PubMed
45) Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, Fauchald P:Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64:979-983, 1997.
PubMed
46) Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ:Late prednisone withdrawal in cyclosporine-treated kidney transplant patients:a randomized study. J Am Soc Nephrol 8:294-301, 1997.
PubMed
47) Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS:A comparison of tacrolimus (FK506) andcyclosporine for immunosuppression after cadaveric renal transplantation. FK506 KidneyTransplant Study Group. Transplantation 63:977-983, 1997.
 
48) Mayer AD, Dmitrewski J, Squifflet Jp, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Neumayer HH, Hauser I, Ericzon BG, Brattstr6 C, Claesson K, MUhlbacher F, PohankaE:Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the preventionof renal allograft rejection:a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436-443, 1997.
 
49) Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N:DIRECT (Diabetes Incidence after Renal Transplantation:Neoral C Monitoring VersusTacrolimus) Investigators:Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7:1506-1514, 2007.
 
50) Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Blom HJ, Sweep FC, Demacker PN, Hilbrands LB:Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 14:1880-1888, 2003.
PubMed
51) American Diabetes Association:Standards of medical care in diabetes-2007. Diabetes Care 30:4-41, 2007.
 
52) エビデンスに基づくCKD診療ガイドライン2009. 日本腎臓学会, 東京医学社, 2009.
 
53) Aakhus S, Dahl K, Wideroe TE:Hyperlipidemia in renal transplant patients. J Intern Med 239:407-415, 1996.
PubMed
54) Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R Wanner C, Wheeler DC, Wilson PW; National Kidney Foundation. Clinical practice guideline for managing dyslipidemias in kidney transplant patients:a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 7 (4 Supll):13-53, 2004.
 
55) Brown JH, Murphy BG, Douglas AF, Short CD, Bhatnagar D, Mackness MI, Hunt LP, Doherty CC, Durrington PN:Influence of immunosuppressive therapy on lipoprotein (a) and other lipoproteins following renal transplantation. Nephron 75:277-282, 1997.
PubMed
56) Gonyea JE, Anderson CF:Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 67:653-657, 1992.
PubMed
57) Hebert PR, Gaziano JM, Chan KS, Hennekens CH:Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview if randomized trials. JAMA 278:313-321, 1997.
PubMed
58) LaRosa JC, He J, VupPuturi S:Effect of statins on risk of coronary disease:ameta-analysis of randomized controlled trials. JAMA 282:2340-2346, 1999.
 
59) Berg AL, Nilson-Ehle P:ACTH lowers serum lipids in steroid-treated hyperlipidemic patients with kidney disease. Kidney Int 50:538-542, 1996.
 
60) Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H:Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70:1352-1359, 2000.
PubMed
61) Hricik DE, Mayes JT, Schulak JA:Independent effects of cyclosporine and prednisolone on posttransplant hypercholesterolemia. Am J Kidney Dis 18:353-358, 1991.
 
62) Ekberg H, Tedsco-Silva H, Demirbas A, Vitko S, Nashan B, gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF:ELITE-Symphony Study. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. N Engl J Med 357:2562-2575, 2007.
 
63) Lentine KL, Brennan DC:S tatin use after renal transplantation:asystemic quality review of trial-based evidence. Nephrol Dial Transplant 19:2378-2386, 2004.
 
64) Holdasas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR:Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of Fluvastatin on cardiac outcomes in renal transplant recipients:a multicentre, randomized, placebo-controlled trial. Lancet 361:2024-2031, 2003.
 
65) Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambuhl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR:ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients:Post-Hoc subgroup analysis of the ALERT-study. Am J Transplant 4:988-995 , 2004.
 
66) Holdaas H. Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, StaMer B, Jardine AG:Assessment of LEscol in Renal Transplantation (ALERT) Study Investgators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin:the ALERT extention study. Am J Transplant 5:2929-2936, 2005.
 
67) Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, ColeE, Maes B, Ambuhl P, Logan JO, Staffler B, Gimpelewicz C:ALERT Study Group. Beneficialeffect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974-980, 2005.
 
68) Seron D, Oppenheimer F, Pallardo LM, Lauzurica R, Errasti P, Gomez-Huertas E, Bosmans JL, Sanchez-Plumed J, Romero R, Marques M, Fulladosa X, Moreso F:Fluvastatin in the Prevention Renal Transplant Vasculopathy:Results of a prospective, randomized, double-blind, placebocontroled trial. Transplantation 86:82-87, 2008.
 
69) 動脈硬化性疾患予防のための脂質異常症治療ガイド 2008年版. 日本動脈硬化学会・編, 協和企画.
 
70) 山田信博:高トリグリセライド血症における治療指標としてのnonHDLコレステロール. 最新医学 63:130-134, 2008.
 
71) Olbricht C, Wnnner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, MangldB, Christians U:Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311-321, 1997.
 
72) Goldberg R, Roth D:Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 62:1559-1564, 1996.
PubMed
73) Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C:Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolims. J Clin Pharmacol 42:222-228, 2001.
 
74) Lipscombe J, Lewis GF, Cattran D, Bargman JM:Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55:39-44, 2001.
PubMed
75) Pascual M, Curtis J, Delmonico FL, Williams WW Jr, Kalil R, Jones P, Cosimi AB, Tolkoff-Rubin N:A prospective, randomized clinical trial of cyclosporine reduction in stable patients greaterthan 12 months after renal transplantation. Transplantation 75:1501-1505, 2003.
 
76) Bosch T:Recent advances in therapeutic apheresis. J Artif Organs 6:1-8, 2003.
PubMed
77) Yanagisawa T, Otsubo O, Nozaki H, Inou T, Sugimoto H, Inoue S, Kuzuhara K:Massive proteinuria after renal transplantation treated LDL-apheresis. Transplant Proc 28:1482-1483, 1996.
PubMed
78) 高尿酸血症・痛風の治療ガイドライン 第1版. (高尿酸血症・痛風の治療ガイドライン作成委員会・編), 日本痛風・核酸代謝学会, 2002.
 
79) 藤森新, 伊藤洋, 小片展之, 渡辺浩之, 松浦久, 山内俊一:わが国の高尿酸血症・痛風は増え続けていない. 痛風と核酸代謝 30:13-19, 2006.
 
80) 冨田眞佐子, 水野正一:高尿酸血症は増加しているか?-性差を中心に. 痛風と核酸代謝 30:1-5, 2006.
 
81) Costa de Oliveira CM, Mota MU, Mota RS, Nobrega JO, Melo DS, Vieira AS, Fernandes PF, Campos HD, Evangelista JB Jr.:Prevalence and staging of chronic kidney disease in renal transplant recipients. Clin Transplant 23:628-636, 2009.
 
82) Bandukwala F, Huang M, Prasad GV:Role of uric acid in post-renal transplantation hypertension. Transplant Proc 41:1634-1636, 2009.
PubMed
83) Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, Burckhardt G:Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13) . J Biol Chem 283:16332-16341, 2008.
PubMed
84) Kanbay M, Akcay A, Huddam B, Usluogullari CA, Arat Z, Ozdemir FN, Haberal M:Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 37:3119-3120, 2005.
PubMed
85) Zawiasa A, Szklarek-Kubicka M, Fijalkowska-Morawska J, Nowak D, Rysz J, Mamelka B, NowickiM:Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipientstreated with cyclosporine or tacrolimus. Transplant Proc 41:188-191, 2009.
 
86) Ishikawa I, Maekawa S, Saito T, Horiguchi T, Shinoda A, Ishii H:Mizoribine-inducedhyperuricemia, Nippon Jinzo Gakkai Shi 28:1353-1357, 1986.
PubMed
87) アンケート調査:ミゾリビンと尿酸値変動. Therapeutic Research 26:647-649, 2005.
Medical*Online
88) Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ:Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 17:1791-1795, 2006.
PubMed
89) Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I:Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320:211-217, 2007.
PubMed
90) Akgul A, Bilgic A, Ibis A, Ozdemir FN, Arat Z, Haberal M:Is uric acid a predictive factor forgraft dysfunction in renal transplant recipients? Transplant Proc 39:1023-1026, 2007.
 
91) Akalin E, Ganeshan SV, Winston J, Muntner P:Hyperuricemia is associated with the developmentof the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 86:652-658, 2008.
 
92) Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV:Association of uric acid withinflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 103:867-871, 2009.
PubMed
93) Min SI, Yun IJ, Kang JM, Park YJ, Min SK, Ahn C, Kim SJ, Ha J:Moderate-to-severe early-onsethyperuricaemia:ap rognostic marker of long-term kidney transplant outcome. Nephrol DialTransplant 24:2584-2590, 2009.
 
94) Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H:Molecular identification of a renal urate anion exchanger that regulates bloodurate levels. Nature 417:447-452, 2002.
PubMed
95) Talaat KM, el-Sheikh AR:The effect of mild hyperuricemia on urinary transforming growthfactor beta and the progression of chronic kidney disease. Am J Nephrol 27:435-440, 2007.
 
96) Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe, Herrera-Acosta J, Mazzali M:Is there a pathogenetic role for uric acid in hypertension andcardiovascular and renal disease? Hypertension 41:1183-1190, 2003.
 
97) Bastow MD, Durrington PN, Ishola M:Hypertriglyceridemia and hyperuricemia:effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37:217-220, 1988.
 
98) 肥満症治療ガイドライン2006. 肥満症治療ガイドライン作成委員会. 日本肥満学会誌 臨時増刊号, 2006.
 
99) Kent PS:Issues of obesity in kidney transplantation. J Ren Nutr 17:107-113, 2007.
PubMed
100) Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM:KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (Supple 3):64-80, 2009.
 
101) Gore JL, Pham PT, Danovitch GM, Wilkinson AH, Rosenthal JT, Lipshutz GS, Singer JS:Obesity and outcome following renal transplantation. Am J Transplant 6:357-363, 2006.
PubMed
102) Segev DL, Simpkins CE, Thompson RE, Locke JE, Warren DS, Montgomery RA:Obesity impacts access to kidney transplantation. J Am Soc Nephrol 19:349-355, 2008.
 
103) Clunk JM, Lin CY, Curtis JJ:Variables affecting weight gain in renal transplant recipients, Am J Kid Dis 38:349-353, 2001.
PubMed
104) Johnson CP, Gallagher-Lepak S, Zhu YR, Porth C, Kelber S, Roza AM, Adams MB:Factors influencing weight gain after renal transplantation. Transplantation 56:822-827, 1993.
PubMed
105) Drafts HH, Anjum MR, Wynn JJ, Mulloy LL, Bowley JN, Humphries AL:The impact of pre-transplant obesity on renal transplant outcomes. Clin Transplant 11:493-496, 1997.
PubMed
106) Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM:One-year post-transplant weight gain is a risk factor for graftloss. Am J Transplant 5:2922-2928 , 2005.
 
107) Reaven GM:Banting lecture 1988. Role of insulin resistance in humen disease. Diabetes 37:1595-1607, 1988.
 
108) World Health Organization:Definition, Diagnosis and Classification of Diabetes mellitus and Its Complications. Part I:Diagnosis and classification of Diabetes Mellitus, World Health Organization, Geneva, 1999.
PubMed
109) Bagby SP:Obesity-initiated mataboloc syndrome and the kidney:a recipe for chronic kidney disease? Am J Soc Nephrol 15:2775-2791, 2004.
 
110) Kurella M, Lo JC, Chertow GM:Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134-2140, 2005.
PubMed
111) Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K:Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 69:369-374, 2006.
PubMed
112) 竹内宏, 斎藤重幸, 高木寛, 大西浩文, 大畑純一, 磯辺健, 藤原槇, 赤坂憲, 島本和明:日本人男性におけるmetabolic syndromeとインスリン抵抗性の検討-端野・壮瞥町研究. 糖尿病 46:739-744, 2003.
 
113) Marcen R:Cardiovascular risk factors in renal transplantation-current controversies. Nephrol Dial Transplant 21 (Suppl 3):38-41, 2006.
 
114) de Vries AP, Bakker SJ, van Son WJ, van der Heide JJ, Ploeg RJ:The HT, de Jong PE, Gans RO:Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 4:1675-1683, 2004.
 
115) Dimeny EM:Cardiovascular disease after renal transplantation. Kidney Int 61:78-84, 2002.
 
116) Adams PL:Long-term patient survival:strategies to improve overall health. Am J Kidney Dis 47 (Suppl 2):65-85, 2006.
 
117) Satyan S, Rocher LL:Impact of kidney transplantation on the progression of cardiovascular disease. Adv Chronic Kidney Dis 11:274-293, 2004.
PubMed
118) 西慎一, 下条文武:慢性腎臓病と腎移植. 移植 42:342-346, 2007.
 
119) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会誌 94:794-809, 2005.
 
120) Mange KC, Cizman B, Joffe M, Feldman HI:Arterial hypertension and renal allograft survival. JAMA 283:633-638, 2000.
PubMed
121) Bellinghieri G, Bernardi A, Piva M, Pati T, Stoppa F, Scaramuzzzo P, Garizzo O, Santoro D, Savica V, Bucciante G:Metabolic syndrome after kidney transplantation. J of Renal Nutrition 19:105-110, 2009.
 
122) Sui W, Zou H, Zou G, Yan Q, Chen H, Che W, Xie S:Clinical study of the risk factors of insulin resistance and metaboloic syndrome after kidney transplantation. Transplant Immunol 20:95-98, 2008.
 
123) Naganuma T, Uchida J, Kinoshita Y, Kuroki Y, Takemoto Y, Yoshimura R, Sugimura K, Nakatani T:The prevalence of metabolic syndrome in Japanese renal transplant recipients. Nephrogy 12:413-417, 2007.
 
124) Kishikawa H, Nishimura K, Kato T, Kobayashi Y, Arichi N, Okuno A, Fujii N, Kyo M, Takahara, Ichikawa Y:Prevalence of the metabolic syndrome in kidney transplantation. Transplant Proc 41:181-183, 2009.
PubMed
125) 西慎一, 下条文武:腎移植患者のメタボリックシンドローム. 腎と透析 65:397-400, 2008.
Medical*Online
126) Meier-Kriesche HU, Arndorfer JA, Kaplan B:The impact of body mass index on renal transplant outcomes:a significant independent risk factor for graft failure and patients death. Transplantation 73:70-74, 2002.
PubMed
127) Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, Hortal L, Fernandez A, Gracia JJ, Velazquez S, Hernandez D, Salido E, Torres A:Impact of metabolic syndorome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48 (1):134-143, 2006.
 
128) Faenza A, Fuga G, Nardo B, Donati G, Cianciolo, G, Scolari MP, Stefoni S:Metabokic syndorome after kidney transplantation. Transplant Proc 39 (6):1843-1846 , 2007.
 
129) Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ:Association between obesity and kidney disease:a systematic review nad meta-analysis. Kidney Int 73:19-33, 2008.
 
130) Gore JL, Pham PT, Danovitch GM, Wilkinson AH, Rosenthal JT, Lipshutz GS, Singer JS:Obesity and outcome following renal transplantation. Am J Transplant 6:357-363, 2006.
PubMed
131) Guida B, Trio R, Laccetti R, Nastasi A, Salvi E, Perrino NR, Caputo C, Rotaia E, Fedevico S, Sabbatini M:Role of dietary intervention on metabolic abnormalities and nutritional status after renal transplantation, Nephrol Dial Transplaint 22:3304-3310, 2007.
 
132) Meier-Krieche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, Kaplan B:The effect of body mass index on long-term renal allograft survival. Transplantation 68:1294-1297, 1999.
 
133) 中川由紀, 斎藤和英, 高橋公太:腎移植患者の食事療法. CKD(慢性腎臓病)の食事療法. 腎と透析 63:831-834, 2007.
 
134) Rike AH, Mogilisthetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES:Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplant patients:comparison of early steroid withdrawal and chronic steroids. Clin Transplant 22:229-235, 2008.
 
135) Fine RN:Management of growth retardation in pediatric recipients of renal allografts. Nature Clinical Practice Nephrology 3:318-324, 2007.
PubMed
136) Tejani A, Fine R, Alexander S, Harmon W, Stablein D:Factors predictive of sustained growth in children after renal transplantation. J Pediatr 122:397-402, 1993.
PubMed
137) Hokken-Koelega ACS, van Zaal MA, van Bergen W, de Ridder MA, Stijnen T, Wolff ED, de Jong RC, Donckerwolcke RA, de Muinck Keizer-Schrama SM, Drop SL:Final height and its predictive factors after renal transplantation in childhood. Pediatr Res 36:323-328, 1994.
 
138) 服部元史:小児慢性腎不全患者の成長. 今日の移植 20:341-348, 2007.
Medical*Online
139) Travis LB, Chesney R, McEnery P, Moel D, Pennisi A, Potter D, Talwalkar YB, Wolff E:Growth and glucocorticoids in children with kidney disease. Kidney Int 14:365-368, 1978.
PubMed
140) Broyer M, Guest G, Gagnadoux MF:Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J pediatr 120:721-725 , 1992.
PubMed
141) 高橋勉, 稲葉進, 大島忠幸, 石原俊二, 豊田由紀, 黒瀬杏子, 高井里香, 吉田礼子, 岡田敏夫, 高田恒郎, 柳原俊雄:小児特発性ネフローゼ症候群の身長発育に関する検討-ステロイド薬との関係. 日児誌 95:1850-1855, 1991.
 
142) Nissel R, Brazda I, Feneberg R, Wigger M, Greiner C, Querfeld U, Haffner D:Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 66:792-800, 2004.
PubMed
143) Schaefer F, Seidel C, Binding A, Gasser T, Largo RH, Prader A, Scharer K:Pubertal growth in chronic renal failure. Pediatr Res 28:5-10, 1990.
PubMed
144) van Diemen-Steenvoorde R, Donckerwolcke RA, Brackel H, Wolff ED, de Jong MC:Growth and sexual matration in children after kidney transplantation. J Pediatr 110:351-356, 1987.
 
145) Motoyama O, Hasegawa A, Ohara T, Satoh M, Shishido S, Honda M, Tsuzuki K, Kinukawa T, Hattori M, Ito K, Ogawa O, Yanagihara T, Saito K, Takahashi K, Ohshima S:A prospective trial of steroid withdrawal after renal transplantation treated with cyclosporine and mizoribine in children:results obtained between 1990 and 2003. Pediatr Transplant 9:232-238, 2005.
PubMed
146) Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR:Growth failure, risk of hospitalization and death for children with end-stage renal disease. Pediatr Nephrol 17:450-455, 2002.
PubMed
147) Broyer M, Le BC, Charbit M, Guest, G, Tete MJ, Gagnadoux, MF, Niaudet P:Long-term social outcome of children after kidney transplantation. Transplantation 77:1033-1037, 2004.
 
148) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (Suppl 3):104-105, 2009.
 
149) Rees L:Growth, nutrition, and pubertal development. Evidence-based Nephrology. (eds. Molony D, Craig J) , Blackwell Publishing, 2009, p654-668.
 
150) Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Hakala TR, Fung JJ, Simmons RL, Starzl TE, Shapiro R:Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 70:760-764, 2000.
PubMed
151) Sarwal MM, Benfield M, Ettenger R, Dharnidharka V, Mathias R, McDonald R, Harmon W, Kershaw D, Vehaskari V, Kamil E, Baluarte H, Warady B, Ikel D, Bridges N, Salvatierra O:One year results of a prospective, randomized, multicenter trial of steroid avoidance in pediatric renal transplantation. Am J Transplant 8 (Suppl S2):192, 2008.
 
152) 田中敏章:思春期の性成熟と成長. 小児科学 第3版. (内山聖・他・編), 医学書院, 2008, p17-19.
 
153) Haffner D, Nissel R:Growth and puberty in chronic kidney disease. In Comprehensive Pediatric Nephrology. (Edited by Geary DF and Schaefer F) , Mosby, 2008, p709-732.
 
154) Hokken-Koelega A, Stijnen T, de Jong RC, Donckerwolcke RA, Groothoff JW, Wolff ED, Blum WF, de Muinck Keizer-Schrama SM, Drop SL:A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplantation. Kidney Int 6 (Suppl):128-134, 1996.
 
155) Maxwell H, Rees L:Randomized controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. Arch Dis Child 79:481-487, 1998.
PubMed
156) Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M:Effects of growth hormone in short children after renal transplantation (French Society of Pediatric Nephrology) . Pediatr Nephrol 12:437-446, 1998.
PubMed
157) Fine RN, Stablein D, Cohen AH, Tejani A and Kohaut E:Recombinant human growth hormone post-renal transplantation in children:arandomized controlled study of the NAPRTCS. Kidney Int 62:688-696, 2002.
 
158) Tyden G, Wernersson A, Sandberg J, Berg U:Development of renal cell carcinoma in living donor grafts. Transplantation 70:1650-1656, 2000.
PubMed
159) Mehls O, Wilton P, Lilien M, Berg U, Broyer M, Rizzoni G, Waldherr R, Opelz G:Does growth hormone treatment affect the risk of post-transplant renal cancer? Pediatr Nephrol 17:984-989, 2002.
PubMed
160) Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS:Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 8:87-90, 2004.
 

書評

最近チェックした商品履歴

Loading...